Franklin Resources Inc. Has $1.46 Billion Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Franklin Resources Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,045,210 shares of the biopharmaceutical company’s stock after purchasing an additional 149,124 shares during the period. Franklin Resources Inc. owned 1.86% of Regeneron Pharmaceuticals worth $1,456,864,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. D.A. Davidson & CO. increased its stake in shares of Regeneron Pharmaceuticals by 5.1% in the third quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock valued at $863,000 after buying an additional 40 shares during the period. Quantbot Technologies LP bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $151,000. Public Sector Pension Investment Board increased its position in shares of Regeneron Pharmaceuticals by 13.0% during the third quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company’s stock worth $4,563,000 after buying an additional 500 shares during the period. Hantz Financial Services Inc. boosted its position in Regeneron Pharmaceuticals by 87.2% during the third quarter. Hantz Financial Services Inc. now owns 73 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 34 shares during the last quarter. Finally, Captrust Financial Advisors lifted its stake in Regeneron Pharmaceuticals by 3.4% in the third quarter. Captrust Financial Advisors now owns 9,130 shares of the biopharmaceutical company’s stock valued at $9,597,000 after buying an additional 296 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Robert W. Baird decreased their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $637.36 on Monday. The company has a 50-day moving average price of $683.88 and a two-hundred day moving average price of $795.57. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $69.68 billion, a PE ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.